The individual data collected throughout patient follow-up constitute crucial information for assessing the risk of a clinical event, and eventually for adapting a therapeutic strategy. Joint models and landmark models have been proposed to compute individual dynamic predictions from repeated measures to one or two markers. However, they hardly extend to the case where the complete patient history includes much more repeated markers possibly. Our objective was thus to propose a solution for the dynamic prediction of a health event that may exploit repeated measures of a possibly large number of markers. We combined a landmark approach extended to endogenous markers history with machine learning methods adapted to survival data. Each marker trajectory is modeled using the information collected up to landmark time, and summary variables that best capture the individual trajectories are derived. These summaries and additional covariates are then included in different prediction methods. To handle a possibly large dimensional history, we rely on machine learning methods adapted to survival data, namely regularized regressions and random survival forests, to predict the event from the landmark time, and we show how they can be combined into a superlearner. Then, the performances are evaluated by cross-validation using estimators of Brier Score and the area under the Receiver Operating Characteristic curve adapted to censored data. We demonstrate in a simulation study the benefits of machine learning survival methods over standard survival models, especially in the case of numerous and/or nonlinear relationships between the predictors and the event. We then applied the methodology in two prediction contexts: a clinical context with the prediction of death for patients with primary biliary cholangitis, and a public health context with the prediction of death in the general elderly population at different ages. Our methodology, implemented in R, enables the prediction of an event using the entire longitudinal patient history, even when the number of repeated markers is large. Although introduced with mixed models for the repeated markers and methods for a single right censored time-to-event, our method can be used with any other appropriate modeling technique for the markers and can be easily extended to competing risks setting.
The cause-specific cumulative incidence function (CIF) quantifies the subject-specific disease risk with competing risk outcome. With longitudinally collected biomarker data, it is of interest to dynamically update the predicted CIF by incorporating the most recent biomarker as well as the cumulating longitudinal history. Motivated by a longitudinal cohort study of chronic kidney disease, we propose a framework for dynamic prediction of end stage renal disease using multivariate longitudinal biomarkers, accounting for the competing risk of death. The proposed framework extends the landmark sur…
Biomarker measurements can be relatively easy and quick to obtain and they are useful to investigate whether a compound works as intended on a mechanistic, pharmacological level. In some situations, it is realistic to assume that patients, whose post-baseline biomarker levels indicate that they do not sufficiently respond to the drug, are also unlikely to respond on clinically relevant long term outcomes (such as time-to-event). However the determination of the treatment effect in the subgroup of patients that sufficiently respond to the drug according to their biomarker levels is not straight…
We are interested in survival analysis of hemodialysis patients for whom several biomarkers are recorded over time. Motivated by this challenging problem, we propose a general framework for multivariate joint longitudinal-survival modeling that can be used to examine the association between several longitudinally recorded covariates and a time-to-event endpoint. Our method allows for simultaneous modeling of longitudinal covariates by taking their correlation into account. This leads to a more efficient method for modeling their trajectories over time, and hence, it can better capture their re…
A key question in clinical practice is accurate prediction of patient prognosis. To this end, nowadays, physicians have at their disposal a variety of tests and biomarkers to aid them in optimizing medical care. These tests are often performed on a regular basis in order to closely follow the progression of the disease. In this setting it is of medical interest to optimally utilize the recorded information and provide medically-relevant summary measures, such as survival probabilities, that will aid in decision making. In this work we present and compare two statistical techniques that provide…
Often in Phase 3 clinical trials measuring a long-term time-to-event endpoint, such as overall survival or progression-free survival, investigators also collect repeated measures on biomarkers which may be predictive of the primary endpoint. Although these data may not be leveraged directly to support early stopping decisions, can we make greater use of these data to increase efficiency and improve interim decision making? We present a joint model for longitudinal and time-to-event data and a method which establishes the distribution of successive estimates of parameters in the joint model acr…
We propose a flexible joint longitudinal-survival framework to examine the association between longitudinally collected biomarkers and a time-to-event endpoint. More specifically, we use our method for analyzing the survival outcome of end-stage renal disease patients with time-varying serum albumin measurements. Our proposed method is robust to common parametric assumptions in that it avoids explicit distributional assumptions on longitudinal measures and allows for subject-specific baseline hazard in the survival component. Fully joint estimation is performed to account for the uncertainty i…
The development of targeted therapies, which benefit only a subgroup of patients treated for a given type of cancer, has been extremely attractive to many investigators. Adaptive seamless phase II/III designs in oncology clinical trials with interim analyses for subpopulation selection could be used if pre-defined biomarker hypothesis exists. We consider the interim analysis using time-to-event endpoints, e.g., overall survival (OS) and progression-free survival (PFS), to identify whether the whole population or only the biomarker-positive population should be continued into the subsequent sta…
Recently, the intervention calculus when the DAG is absent (IDA) method was developed to estimate lower bounds of causal effects from observational high-dimensional data. Originally it was introduced to assess the effect of baseline biomarkers which do not vary over time. However, in many clinical settings, measurements of biomarkers are repeated at fixed time points during treatment exposure and, therefore, this method need to be extended. The purpose of this paper is then to extend the first step of the IDA, the Peter Clarks (PC)-algorithm, to a time-dependent exposure in the context of a bi…
Stein-Encoder: A White-Box Supervised Encoder via Stein Identities in Multi-Modal Studies
School of Mathematics, South China University of Technology(华南理工大学数学学院);Department of Biostatistics and Epidemiology, University of California, Berkeley(加州大学伯克利分校生物统计学与流行病学系);School of Data Science, The Chinese University of Hong Kong, Shenzhen(香港中文大学(深圳)数据科学学院);Department of Mathematics, Hong Kong University of Science and Technology(香港科技大学数学系)
We present a general approach to synthesizing evidence of time-to-event endpoints in meta-analyses of aggregate data (AD). Our work goes beyond most previous meta-analytic research by using reconstructed survival data as a source of information. A Bayesian multilevel regression model, called the "meta-analysis of reconstructed survival data" (MARS), is introduced, by modeling and integrating reconstructed survival information with other types of summary data, to estimate the hazard ratio function and survival probabilities. The method attempts to reduce selection bias, and relaxes the presumpt…
Efficient estimation of cumulative incidence curves via data fusion with surrogates: application to integrated analysis of vaccine trial and immunobridging data
University of Cambridge(剑桥大学);Fred Hutchinson Cancer Center(弗雷德·哈钦森癌症中心);Ghent University(根特大学)
Ensemble Machine Learning and Statistical Procedures for Dynamic Predictions of Time-to-Event Outcomes
Department of Biostatistics, Erasmus University Medical Center(埃因霍温医学院生物统计学系);Department of Epidemiology, Erasmus University Medical Center(埃因霍温医学院流行病学系);Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis, European Reference Network on Hepatological Diseases (ERN Rare-Liver), Saint-Antoine Hospital, Assistance Publique - Hôpitaux de Paris(欧洲肝病参考网络(ERN Rare-Liver)炎症性胆汁疾病与自身免疫性肝炎参考中心,圣安东尼医院,法国巴黎国家医学研究院(Inserm)UMR_S938,圣安东尼研究中心,索邦大学,法国);Inserm UMR_S938, Saint-Antoine Research Center, Sorbonne University, Paris, France(米兰Bicocca大学医学与外科系,意大利);Department of Medicine and Surgery, University of Milan Bicocca, Italy(迈阿密大学米勒医学院,美国);Miller School of Medicine, University of Miami, United States of America(巴塞罗那医院病毒性、毒性及代谢性肝病科,西班牙);Viral, Toxic and Metabolic Hepatopathies, Hospital Clínic de Barcelona, Spain(东京大学医学部医学系,日本);Department of Medicine, Teikyo University School of Medicine, Japan(伯明翰大学生物医学研究中心及肝脏研究中心,英国);Biomedical Research Unit & Centre for Liver Research, University of Birmingham, United Kingdom(布宜诺斯艾利斯医院胃肠病科及肝病科,阿根廷);Division of Gastroenterology & Hepatology, Hospital Italiano de Buenos Aires, Argentina(多伦多总医院肝脏疾病中心,加拿大);Centre for Liver Disease, Toronto General Hospital, Canada
We present the findings of "The Alzheimer's Disease Prediction Of Longitudinal Evolution" (TADPOLE) Challenge, which compared the performance of 92 algorithms from 33 international teams at predicting the future trajectory of 219 individuals at risk of Alzheimer's disease. Challenge participants were required to make a prediction, for each month of a 5-year future time period, of three key outcomes: clinical diagnosis, Alzheimer's Disease Assessment Scale Cognitive Subdomain (ADAS-Cog13), and total volume of the ventricles. The methods used by challenge participants included multivariate linea…
University of Potsdam(波茨坦大学);Institute of Mathematics(数学研究所);Institute of Pharmacy(药剂学研究所)
Model-informed precision dosing (MIPD) using therapeutic drug/biomarker monitoring offers the opportunity to significantly improve the efficacy and safety of drug therapies. Current strategies comprise model-informed dosing tables or are based on maximum a-posteriori estimates. These approaches, however, lack a quantification of uncertainty and/or consider only part of the available patient-specific information. We propose three novel approaches for MIPD employing Bayesian data assimilation (DA) and/or reinforcement learning (RL) to control neutropenia, the major dose-limiting side effect in a…
Georgia Institute of Technology(佐治亚理工学院);Emory University(埃默里大学)
Cancer survival prediction is an active area of research that can help prevent unnecessary therapies and improve patient's quality of life. Gene expression profiling is being widely used in cancer studies to discover informative biomarkers that aid predict different clinical endpoint prediction. We use multiple modalities of data derived from RNA deep-sequencing (RNA-seq) to predict survival of cancer patients. Despite the wealth of information available in expression profiles of cancer tumors, fulfilling the aforementioned objective remains a big challenge, for the most part, due to the pauci…